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Abstract
The association of inheritance of different apolipoprotein E (APOE, gene; apoE, protein) alleles with the risk and rate of
onset of Alzheimer’s disease (AD) is now well established and widely confirmed. While there are now a collection of
hypotheses concerning the specific relationship of APOE polymorphisms to various phenotypic manifestations of AD, no
single compelling theory has been tested and universally accepted. The only clear fact emerging during the past 6 years is that
differences in APOE genotype affect the average rate of disease onset as a predictable function of the inheritance of this
polymorphic gene. Methods now exist to enable experimental designs to study the metabolic effects of inheriting different
APOE alleles, addressing what differences that may be present for many years, perhaps over the entire lifetime, can lead to
earlier or later manifestations of the disease and are therapeutically tractable. This review summarizes part of an
experimental approach to identify biological pathways influenced by the different APOE polymorphisms that are relevant to
the pathogenesis of AD. ß 2000 Published by Elsevier Science B.V.
Keywords: Apolipoprotein E; Alzheimer’s disease; Pharmacogenomics; Di¡erential gene expression; mRNA; Polymorphism
1. Introduction
Is Alzheimer’s disease (AD) something that devel-
ops late in life because certain neuropathological
phenomena lead to neuronal degeneration, or does
AD develop over many years because of a biased
metabolism that leads to certain recognizable conse-
quences? Are these hypotheses mutually exclusive?
Hypothesis-driven research has favored some form
of ‘something causes neurodegeneration’ testing.
For the past decade and a half, a circular argument
has prevailed: one that states that since AD is diag-
nosed by the de¢ned presence of amyloid-containing
plaques, alterations of amyloid precursor protein
(APP) or the amyloid L-peptide (AL) metabolism
must cause AD [1]. Similar phenotype/causality argu-
ments can be made for formation of paired helical
¢laments from tau protein leading to neuro¢brillary
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tangles. The rapid pace of gene discovery for mono-
genic diseases has also emphasized this scienti¢c ap-
proach, usually generalizing the speculations to cover
a broader estate of disease.
Susceptibility genes, like APOE (the apolipopro-
tein E gene) for AD, are not associated with full
penetrance and have other associated environmental
interactions. It is di⁄cult to generalize about suscep-
tibility genes, since APOE is still the only example of
a susceptibility gene for AD that has been con¢rmed
widely. There are numerous reports of other poten-
tial susceptibility polymorphisms in AD. None have
been as broadly replicated as APOE, and other pop-
ulation-speci¢c e¡ects with these less common poly-
morphisms cannot be ruled out [2]. APOE polymor-
phisms have been associated with additional
phenotypic or environmental phenomena, such as
chronic and acute head injury, response to intracere-
bral hemorrhage and recovery from cardiopulmo-
nary bypass surgery and stroke [3^11]. The fact
that these environmental interactions may occur ear-
lier in life and without any concurrent manifestations
of AD pathology supports the notion that a lifelong
biased metabolism may be present in the brain, de-
pending on the inherited APOE genotype.
Current tools for pharmacogenomic analyses, in-
cluding di¡erential gene expression, yeast two-hybrid
interactions, proteomics and high resolution cell
mapping, allow experimental designs that can simul-
taneously analyze multiple potential variants. In the
past, such an approach could be termed ‘a ¢shing
expedition’. Now, like other ¢shing expeditions,
high performance, rapid, accurate and novel experi-
ments can function like high resolution sonar detec-
tors on real ¢shing trips. Whether or not a single
hypothesis, or multiple simultaneous e¡ects, charac-
terizes the pathogenesis of AD can now be subjected
to pharmacogenomic methodologies.
The pharmaceutical industry has recently incorpo-
rated pharmacogenomic strategies aimed at detecting
genetically relevant targets for high throughput drug
screening. The fact that multiple metabolic pathways
may be highlighted using a particular experimental
approach simply allows the identi¢cation of multiple
targets. The targets can be prioritized on the basis of
expected side e¡ects, disease validity and chemical
tractability to allow production of agonists or antag-
onists to be tested in experimental animals or man.
2. Biochemical background
ApoE is a lipid transport molecule that is a con-
stituent of very low density lipoproteins, a subclass
of high density lipoproteins and chylomicrons [12].
Cellular uptake of lipid complexes is mediated
through the binding of lipid-complexed apoE to the
low density lipoprotein (LDL) receptor and other
related receptors [13]. APOE is located within an
apolipoprotein gene family on human chromosome
19 and has three common alleles, designated O2, O3
and O4. These genetic variations result in amino acid
substitutions (arginine or cysteine) at positions 112
and 158 of the protein [14]. In most Caucasian pop-
ulations, APOE3/3 is the most common genotype
and O3 is the most common allele; O4 and O2 are
considered variants. ApoE4 has normal LDL recep-
tor binding, but is associated with elevated plasma
cholesterol and LDL levels. The apoE2 protein binds
poorly to the LDL receptor, and APOE2/2 is the
most common genotype associated with type III hy-
perlipoproteinemia [12].
The largest amount of APOE mRNA is found in
the liver; the second largest concentration, approxi-
mately one-third the level seen in liver, is in the brain
[15,16]. Brain apoE is synthesized locally, not by the
liver, as shown in liver transplant patients, and is the
major apolipoprotein in cerebrospinal £uid [17,18].
Interesting models involving the storage and redis-
tribution of cholesterol following peripheral and
CNS injury were proposed about a decade ago [19^
23]. Other functions of apoE in the nervous system,
unrelated to lipid transport, have also been pro-
posed. These include the possibility of it acting as a
neurotrophic factor or modulator of neurotrophin
activity, an antioxidant and a mediator of immune
responses [24^31]. With regard to the pathophysiol-
ogy of AD, the two most popular hypotheses con-
cern amyloid plaques and neuro¢brillary tangles, the
two pathological hallmarks of AD. In these hypoth-
eses, apoE is thought to have an e¡ect on amyloid
deposition or in the stabilization of microtubules
[1,32^36].
3. Genetic background
The original reports of the association of APOE4
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with late-onset familial and sporadic AD were rap-
idly and widely con¢rmed throughout the world [37^
47]. Later studies demonstrated that the O4 allele is
also associated with sporadic early-onset AD and
early-onset AD families without presenilin or APP
mutations [48^52]. These multiple con¢rmations es-
tablished the O4 allele as the most important genetic
marker for risk of disease identi¢ed so far, account-
ing for approximately 50% of the genetic component
of AD [53]. The association of APOE4 and AD in
African-Americans and Hispanics remains controver-
sial and may be absent in a very small sample of
Nigerian AD cases and controls [54^57].
The inheritance of each APOE4 allele is associated
with an average earlier onset of disease of 6^8 years
compared to inheritance of two APOE3 alleles [58].
Each APOE2 allele is associated with an additional
6^8 years later onset. Thus the mean onset for
APOE4/4 homozygotes is less than 70 years of age,
while APOE2/3 individuals have a mean onset great-
er than 90 years of age. It is important to note that
these cumulative risk data are drawn from large pop-
ulation studies and cannot be applied to individuals
curious about their risk for developing AD. For this
reason, the use of APOE genetic testing as it relates
to AD is speci¢cally restricted to patients suspected
of having the disease. The cumulative risk data have
been con¢rmed in multiple populations and predict
the characteristics of AD in di¡erent groups
[43,55,59^65]. In Japan, where the allele frequency
of APOE4 is about half that in the USA, and where
the APOE2 allele is also less frequent, most of the
APOE4-associated AD patients have the APOE3/4
genotype [44,47,66,67]. In the USA, 2^3% of the
population have the APOE4/4 genotype, while in Ja-
pan it is less than 0.5%. Thus there are many fewer
people with an average age of onset less than 70
years, and more with onset 76^78 years. There is
also a lower frequency of AD in Japan. This con-
forms exactly with the long-standing clinical data
from Japan: there is less AD and an older age of
onset (76^78 years) [68].
Thus the cumulative rate of AD development in a
population is related to the type of APOE genotype
inherited, independent of any mechanistic hypothe-
sis. Can we design experiments that can assess the
e¡ect of di¡erent APOE alleles on the metabolism of
the brain while controlling for other variables? A
secondary question is whether the data generated
from experiments comparing brains expressing di¡er-
ent human APOE alleles intersect with prevailing
causative hypotheses and/or shed new and unex-
pected light on brain metabolic biases.
4. Experimental design
How can we model the metabolic di¡erences be-
tween brains inheriting human APOE4 alleles versus
human APOE3 alleles and insure that the locations
of APOE brain expression in the model re£ect that
of human brain? Human brain expresses APOE
mRNA in neurons as well as glia, distinguishing
this expression pattern from rodents [69]. Human
brain normally demonstrates particularly dense and
complete immunostaining of astrocytic glial cells
with intense immunoreactivity present within the
thin rim of cytoplasm surrounding the nucleus but
also in the processes as they spread throughout the
neuropil and as they end on blood vessels. In con-
trast, neuronal immunoreactivity is less intense and
con¢ned to the region of cytoplasm just around the
nucleus and in proximal processes. There are two
very distinct lines of allele-speci¢c, human APOE-
expressing mice under the control of human or
mouse promoters. The ¢rst line contains equal doses
of genomic APOE transgenes on an APOE-de¢cient
(‘knock-out’) background [70]. These animals have
the natural human 5P and 3P human tissue expression
elements present, and apoE localization mimics the
human pattern with neuronal and glial expression. A
second paradigm of human APOE ‘knock-in’ mice
also makes only human APOE mRNA, but does
not have the natural human tissue expression ele-
ments present and does not express APOE in neu-
rons unless a non-physiologic, neuron-speci¢c pro-
moter is used [71^74].
Human apoE protein isoforms can fully substitute
for mouse apoE. Both the human genomic APOE
mice and the human ‘knock-in’ APOE mice live nor-
mal lifespans, and their phenotype can be distin-
guished only by neuronal and glial expression of
apoE protein or mRNA, detected by immunostain-
ing and in situ hybridization respectively. All of these
mice have normal phenotypes, with the exception of
subtle impairments in aged female mice with a rela-
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tively high copy number of human APOE transgenes
arti¢cially driven by a neuronal-speci¢c promoter
[71]. The experimental questions are whether di¡er-
ences in the metabolism of the brains of APOE3 mice
and APOE4 mice exist, and whether the experiments
include neuronal metabolic biases that might be
unique to the mice with neuronal expression of hu-
man APOE.
5. Review of gene expression technology to understand
disease
The ability to measure and compare the levels at
which genes are turned on in animal models or tis-
sues represents a powerful method of identifying
genes associated with diseases, traits and biological
responses to chemicals. Existing methods for gene
expression analysis fall into three groups: transcript
sampling by direct DNA sequencing, transcript am-
pli¢cation and imaging, and hybridization-based ap-
proaches [75^89]. Serial analysis of gene expression,
the most cost-e¡ective gene transcript-counting tech-
nique, produces short gene fragments that are con-
catenated and sequenced [85]. One can then compare
the relative number of times each short sequence was
recovered in di¡erent samples in order to determine
if there was a di¡erence in gene expression. However,
this technique is limited to those known genes for
which the short fragments have already been se-
quenced. Transcript sequencing following subtractive
hybridization, a method of physically removing the
genes that are in common between two samples in
order to identify a pool of gene di¡erences, also iden-
ti¢es di¡erentially expressed genes, but is limited to
binary comparisons [90]. Transcript imaging ap-
proaches such as di¡erential display, partitioning
by type IIS restriction enzymes, representational dif-
ference analysis and ampli¢ed fragment length poly-
morphism are rapid ways of fragmenting gene se-
quences and displaying them. The gene fragments
can be visually formatted in order to compare and
identify di¡erences in patterns that correspond to
di¡erences in genes being turned on or o¡ [75,77,
Fig. 1. Hybridization-based di¡erential gene expression strategies. A diagram of Glaxo Wellcome’s microarray approach of spotting
sequences for known genes or pieces of genes on a ¢lter or microchip. Extracted RNA is radiolabeled using a reverse transcriptase
(RT) PCR. The radiolabeled probes from a tissue of interest are allowed to anneal with the spotted genes to ¢nd their complementary
sequences. When a gene from a tissue has found a match, the spot will ‘light up’ by whatever detection technique (i.e., phosphoimag-
ing, £uorescence, etc.) is employed. By comparing the patterns of di¡erent samples, one can deduce which genes are up and down
regulated in which samples.
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79,80]. However, each of these techniques requires a
time-consuming cloning and con¢rmation process for
determining the identity of di¡erentially expressed
gene fragments.
The recent development of microarrays has signi¢-
cantly enhanced the capacity of hybridization tech-
niques to identify di¡erences in gene expression
[76,82^84]. Fig. 1 diagrams a microarray approach
of spotting sequences for known genes or pieces of
genes on a ¢lter or microchip and allowing the gene
transcripts from a tissue of interest to anneal with
the spotted genes to ¢nd their complementary se-
quences. When a gene from a tissue has found a
match, the spot will ‘light up’ by whatever detection
technique (i.e., phosphoimaging, £uorescence, etc.) is
employed. By comparing the patterns of di¡erent
samples, one can deduce which genes are turned on
and o¡ in which samples. A practical limitation of
hybridization methods is that appropriate cDNA li-
braries need to be available.
Another approach to gene expression analysis uses
the gene fragmentation strategy of di¡erential dis-
play in order to measure the abundance of known
and novel genes. In addition, the strategy takes ad-
vantage of the known gene sequence databases in
order to predict rapidly the identity of a gene frag-
ment if the gene from which it is derived is already
known. This approach is illustrated in Fig. 2. Iden-
ti¢cation of gene fragments is achieved by treating
samples with restriction enzymes, which cut DNA
speci¢cally and reproducibly in certain regions, fol-
lowed by PCR ampli¢cation. These ampli¢ed frag-
ments are then sized and di¡erences in pattern or
intensity are identi¢ed. The DNA fragments that
are di¡erent are electronically searched in a database
of known genes by length and the enzymes used in
order to identify the gene as a known gene in the
database or as a new gene not in the database. The
new genes are then sequenced, and the known genes
can be studied further immediately.
Hybridization- and gene fragmentation-based
techniques complement each other by their ability
to optimally detect expression variations of medium
to high versus low message copy number. Hybridiza-
tion-based methods are considered ‘closed’ systems,
with data generation depending on the depth and
Fig. 2. Gene fragmentation-based di¡erential gene expression strategy. A £ow chart illustrating the basic steps of GeneCalling, a gene
fragmentation-based approach developed by CuraGen. Double stranded cDNA is digested with a mixture of restriction endonuclease
enzymes to generate cDNA fragments. The fragments are ampli¢ed by PCR and then separated by size using gel electrophoresis. Pat-
terns of altered gene expression are identi¢ed and compared with genome sequence databases of predicted size fragments.
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quality of the spotted cDNA library. Hybridization
approaches are especially useful for detecting di¡er-
ences of abundant to medium expressed messages.
Gene fragmentation and sequencing strategies, on
the other hand, are ‘open’ systems that potentially
detect all di¡erences in gene expression within an
experimental system. These techniques are particu-
larly useful in detecting di¡erences in rare and low
copy number messages. It is possible that expression
di¡erences of the higher copy number genes will be
obscured due to the ampli¢cation step, which could
be non-linear at high expression levels. Both the
closed and open systems detect novel sequences;
however, detection in the closed systems is dependent
on representation on the cDNA grid.
These methods of di¡erential gene expression are
readily applicable to animal models such as trans-
genics. In such a model, a mutant gene may be put
into a mouse that may result in a phenotype or dis-
ease, and the genes that respond to the presence of
the mutant gene by being turned up or down can be
readily identi¢ed. These changes re£ect the transgen-
ic animal’s adaptation to the altered gene, not just a
direct result of the transgenic change. In this type of
study, the proteins encoded by these genes often clus-
ter into biochemical or signal transduction pathways,
o¡ering either elucidation of the disease mecha-
nism(s) or generation of testable hypotheses. These
animal gene markers, once con¢rmed by other com-
plementary means, can be very valuable because
some of them might be excellent targets for small
molecule intervention as therapeutics. As an exten-
sion of gene identi¢cation and con¢rmation in a
transgenic model, the human versions of these genes
may be useful in diagnosing disease at an early
stage or evaluating the response to drug therapy.
Genetic variations within these genes may correlate
with individuals that respond or are resistant to
certain therapies. The use of tests for gene expres-
sion and DNA polymorphisms to triage drug ther-
apy is an emerging science known as pharmacoge-
nomics.
Fig. 3. An experimental design for identifying altered gene expression in APOE transgenic animals. Age-related and APOE allele-spe-
ci¢c alterations in patterns of gene expression can be studied using di¡erential gene expression studies. This schematic depicts one
type of comparison using the gene fragmentation-based approach, GeneCalling. Gene expression patterns are compared in both young
and old transgenic mice, genetically the same except for bearing human genomic fragments that encode APOE4 or APOE3. Three ani-
mals for each comparison point are examined; the bioinformatics of the system allows the noise due to inter-individual variations to
be subtracted so that when APOE4 and APOE3 brains are compared, di¡erences based only on the APOE alleles can be analyzed.
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6. Pharmacogenomic data analyses
When using inbred mice with the same genetic
background except for bearing genomic fragments
di¡ering only in whether APOE3 or APOE4 is
coded, the comparison of otherwise normal brains
would not be expected to demonstrate large di¡er-
ences. The human apoE proteins would be expected
to substitute for all observable mouse functions. By
comparing brains of individual APOE3 or APOE4
animals with others carrying the same allele, one
can measure the noise in a particular pharmacoge-
nomic system. Fig. 3 illustrates a comparison of three
mRNA preparations from three sibling animals with
a single form of human APOE in the gene fragmen-
tation strategy. The bioinformatics of the system al-
lows the noise to be subtracted out so that when
APOE4 and APOE3 brains are compared, di¡erences
based only on the APOE genetic di¡erences can be
displayed. As an extension, gene expression di¡eren-
ces attributable to neuronal expression of human
APOE can be identi¢ed by comparing the APOE
genomic fragment transgenic mice with APOE-tar-
geted replacement mice, which have human APOE
under the in£uence of the natural murine APOE pro-
moter. Furthermore, these comparisons can be allele-
speci¢c. In light of APOE’s role in recovery from
brain stresses, di¡erences in gene expression of trans-
genic animals exposed to speci¢c challenges such as
middle cerebral occlusion, a model of stroke injury,
or experimentally induced head injury can also be
performed.
While the data from such APOE experiments are
not ready to be disclosed and illustrated, Fig. 4 illus-
trates the pathway information of a hypothetical ex-
periment comparing normal and disease tissues.
Identi¢cation of the subtracted peaks provides a sur-
prisingly robust measurement of speci¢c gene expres-
sion di¡erences. Interpretation of these di¡erences
can be illustrated in a convenient format by software
that automatically allows metabolic pathways to be
illustrated.
Similarly, comparisons of proteins that interact
with each other, measured by high throughput yeast
two-hybrid experiments, can be illustrated with sim-
ilar informatics. Proteomic data can also be placed
Fig. 4. General experimental design and outcome in a gene fragmentation-based strategy. The expressed genes in a ‘normal’ versus a
‘diseased’ tissue can be isolated, ampli¢ed by PCR and digested with a mixture of restriction endonucleases. These ampli¢ed fragments
are then sized by gel electrophoresis, and di¡erences in pattern or intensity are identi¢ed. The DNA fragments that are di¡erent are
electronically searched in a database of known genes by length and the enzymes used in order to identify the gene as a known gene
in the database or as a new gene not in the database.
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within the system, correlating expression of proteins
in the same tissues. Of course, when suitably entered
and collected in the same bioinformatic systems, syn-
thesis of overlapping metabolic ¢elds can be readily
identi¢ed.
Integrated bioinformatic systems that incorporate
reproducible functional genomic databases can be
analyzed, with comparisons available in silico be-
cause of the de¢ned genetic variables. Di¡erences in
gene expression as a function of the ages of the ani-
mal, gender di¡erences or pharmacological treat-
ments can all be encompassed by model-integrated,
biotechnical systems. The practical problems are ex-
perimental design, cost and scale and, therefore, the
pharmacogenomic approaches are probably only
available in large, committed RpD organizations.
7. Pharmaceutical targets
Assume that the di¡erential gene experiments and
associated proteomics identi¢ed three metabolic
pathways that were di¡erentially expressed in
APOE3 versus APOE4 animals. They could re£ect
either of two general types: expected results, based
on prior hypotheses in the literature, or unexpected
results. In either case, they share the common feature
of being metabolic enzymes and therefore are gener-
ally tractable for drug development.
Rate-limiting enzymes from each of the three path-
ways can be adapted to high throughput screens for
the identi¢cation of agonist or antagonist compound
lead series, which then may be selected as a possible
therapy. The decision does not matter, only the ex-
perimental plan to perform the next series of experi-
ments.
Suppose we have an agonist series and an antag-
onist series developed from the di¡erential metabo-
lism of APOE4 and APOE3 brains. A possible sec-
ondary screen would be to observe whether the
agonists or antagonists alter amyloid production in
a tissue culture model. This type of secondary screen
is relatively low cost, high throughput and rapid. A
later screen could be to observe whether amyloid
formation occurs earlier in the agonist- or antago-
nist-treated animals. Clearly the therapeutic product
might then be sought in the series that delayed amy-
loid plaque formation. There are certainly other
screens that could be applied. The point is that it
does not really matter whether the investigator’s per-
sonal belief system is that amyloid causes AD, or
that it is a manifestation of an altered metabolism.
A molecular series based on the di¡erences between
APOE4 and APOE3 brains that delayed or halted
amyloid deposition might be a very attractive poten-
tial lead for developing a drug to prevent AD. An
old-fashioned ¢shing expedition using state-of-the-
art ¢sh ¢nding technology!
8. Conclusion
We are entering into a new era of drug discovery
in which genetics and genomics will play a major role
in target selection. Tractable targets for diseases with
a huge unmet need, like AD, will soon be a reality.
Combined with the use of targeted pharmacogenetic
experiments in the drug development process, we will
have new, innovative and e¡ective drugs. We will
also be able to limit adverse events and decrease
the cost of drug development with smaller numbers
of patients and a higher proportion of responders
based on pharmacogenetic pro¢les.
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